Minimally invasive solutions for reflux disorders

Mederi Therapeutics focuses on innovative solutions for diagnosing and treating reflux disorders through its Restech line of products. One of the key technologies is the Dx-pH diagnostic test, which provides clinicians with critical data to accurately assess reflux conditions, particularly in patients with "Silent Reflux." This test allows for a more targeted treatment approach, moving away from a symptom-based diagnosis to a data-driven strategy. The company emphasizes the importance of accurate diagnosis, as studies indicate that symptoms alone cannot reliably determine the presence of laryngopharyngeal reflux (LPR). By utilizing the Dx-pH test, healthcare providers can confidently recommend appropriate treatment plans, ensuring that patients receive the most effective care tailored to their specific reflux patterns.

In addition to diagnostic tools, Mederi Therapeutics offers Stretta therapy, a minimally invasive, non-surgical procedure designed to treat gastroesophageal reflux disease (GERD) and laryngopharyngeal reflux disease (LPRD). This outpatient procedure employs low-power radiofrequency energy to strengthen the lower esophageal sphincter (LES), addressing the underlying functional issues that contribute to reflux symptoms. Stretta therapy has been shown to provide significant and lasting relief for many patients, allowing them to reduce or eliminate their reliance on proton pump inhibitors (PPIs). With over 25,000 procedures performed and extensive clinical studies supporting its safety and efficacy, Stretta represents a valuable alternative for patients seeking relief from chronic reflux without the need for surgery.

United States

Restech offers minimally invasive tools to multiple specialties in order to accurately diagnose and manage reflux, and will continue to create solutions related to the complexity gastric related diseases. Restech’s tools are helping  evolve the standard of care for patients with reflux, and fecal incontinence, providing physicians with the necessary data to transform the algorithm of care for tens of millions of patients.

Mederi Therapeutics

Company Details